Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines

Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment

(2013) H. Reuveni et al.   CANCER RESEARCH

Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing

(2013) E. Heitzer et al.   CANCER RESEARCH

Congenital Goitrous Primary Hypothyroidism in Two German Families Caused by Novel Thyroid Peroxidase (TPO) Gene Mutations

(2013) K. Altmann et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Comprehensive molecular characterization of clear cell renal cell carcinoma

(2013)   NATURE

Circulating tumor cells

(2013) S. C. P. Williams   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Isolation and retrieval of circulating tumor cells using centrifugal forces

(2013) Han Wei Hou et al.   Scientific Reports

Pathogenesis and the Role of ARID1A Mutation in Endometriosis-related Ovarian Neoplasms

(2012) Daichi Maeda et al.   ADVANCES IN ANATOMIC PATHOLOGY

Smac Mimetic LBW242 Sensitizes XIAP-Overexpressing Neuroblastoma Cells for TNF- -Independent Apoptosis

(2012) G. Eschenburg et al.   CANCER RESEARCH

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis

(2012) Matthew F. Kalady et al.   DISEASES OF THE COLON & RECTUM

Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice

(2012) Meredith A. Collins et al.   JOURNAL OF CLINICAL INVESTIGATION

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment

(2012) Ralph P. Tufano et al.   MEDICINE

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis

(2012) Min Yu et al.   NATURE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Comprehensive genomic characterization of squamous cell lung cancers

(2012)   NATURE

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

(2012) Matthieu Le Gallo et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal Tubular HIF-2α Expression Requires VHL Inactivation and Causes Fibrosis and Cysts

(2012) Ruth E. Schietke et al.   PLoS One

A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells

(2012) Eleonora Petrucci et al.   PLoS One

The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

(2012) Gholamreza Safaee Ardekani et al.   PLoS One

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

(2012) M. L. Sos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

(2012) Jennifer N. Wu et al.   Cancer Discovery

Genetic variation in bone morphogenetic protein and colon and rectal cancer

(2011) Martha L. Slattery et al.   INTERNATIONAL JOURNAL OF CANCER

Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas

(2011) Kimberly C Wiegand et al.   JOURNAL OF PATHOLOGY

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays

(2011) Roland Houben et al.   PLoS One

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors

(2011) Lee E. Moore et al.   PLoS Genetics

Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability

(2010) SANG WOOK PARK et al.   APMIS

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas

(2010) Bin Gao et al.   Journal of Thoracic Oncology

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

(2010) Gideon Bollag et al.   NATURE

A method and server for predicting damaging missense mutations

(2010) Ivan A Adzhubei et al.   NATURE METHODS

Gene and drug matrix for personalized cancer therapy

(2010) Tim Harris   NATURE REVIEWS DRUG DISCOVERY

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

(2010) K. J. Dedes et al.   Science Translational Medicine

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

(2009) Martin L. Sos et al.   JOURNAL OF CLINICAL INVESTIGATION

EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

(2008) J. P. Koivunen et al.   CLINICAL CANCER RESEARCH

Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms

(2008) Liang Cheng et al.   HUMAN PATHOLOGY

Patients With Acute Myeloid Leukemia andRASMutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

(2008) Andreas Neubauer et al.   JOURNAL OF CLINICAL ONCOLOGY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Detection of Mutations inEGFRin Circulating Lung-Cancer Cells

(2008) Shyamala Maheswaran et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA